{"id":"ar-301","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immunogenicity/anti-drug antibodies"}]},"_chembl":{"chemblId":"CHEMBL4594526","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AR-301 binds to Pseudomonas aeruginosa exotoxin A, a major virulence factor secreted by the bacterium that inhibits protein synthesis and promotes bacterial survival. By neutralizing this toxin, the drug reduces bacterial pathogenicity and allows the host immune system to more effectively control the infection. This approach is designed to work synergistically with standard antibiotics and the patient's innate immune response.","oneSentence":"AR-301 is a monoclonal antibody that targets and neutralizes Pseudomonas aeruginosa exotoxin A to reduce bacterial virulence and enhance immune clearance in respiratory infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:15.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with Pseudomonas aeruginosa respiratory infection"},{"name":"Ventilator-associated pneumonia caused by Pseudomonas aeruginosa"}]},"trialDetails":[{"nctId":"NCT03816956","phase":"PHASE3","title":"Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301","status":"COMPLETED","sponsor":"Aridis Pharmaceuticals, Inc.","startDate":"2019-05-03","conditions":"Lung Infection, Pneumonia, Ventilator-Associated, Infection, Bacterial","enrollment":174},{"nctId":"NCT01589185","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)","status":"COMPLETED","sponsor":"Aridis Pharmaceuticals, Inc.","startDate":"2012-05","conditions":"Pneumonia Due to Staphylococcus Aureus","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AR-301 (tosatoxumab)"],"phase":"phase_3","status":"active","brandName":"AR-301","genericName":"AR-301","companyName":"Aridis Pharmaceuticals, Inc.","companyId":"aridis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AR-301 is a monoclonal antibody that targets and neutralizes Pseudomonas aeruginosa exotoxin A to reduce bacterial virulence and enhance immune clearance in respiratory infections. Used for Cystic fibrosis with Pseudomonas aeruginosa respiratory infection, Ventilator-associated pneumonia caused by Pseudomonas aeruginosa.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}